As Congress grapples with repealing and replacing the Affordable Care Act, MACRA benchmarking already underway and other rapid changes to the American healthcare system, it has never been more important for rheumatologists to make their voices heard. This is why it’s critical ACR members join or renew their membership in the American Medical Association (AMA)…
The Biomarkers of Lupus Disease Study
Most SLE clinical trials continue standard background medications being taken by patients at entry, based on assumptions that this minimizes the risk of serious flares and that immunologic interference is minimal. These assumptions are not evidence based, but eliminating polypharmacy in trials studying patients with active lupus remains controversial. These researchers tested the withdrawal of immunosuppressants to make SLE trial results more interpretable…
A Look at CPT Codes for Prolonged Services
In the 2017 Medicare physician fee schedule, the CMS officially activated CPT codes 99358 and 99359 as reimbursable codes for non-face-to-face prolonged services performed in the office or outpatient setting, hospital or nursing facility by physicians or other qualified health practitioners (not clinical staff). The CPT codes are defined as 99358: Prolonged evaluation and management service…
NGS Updates E/M Coding Requirements for Examination Component
Effective for dates of service on and after July 1, 2017, the National Government Services (NGS), the Medicare administrative contractor for Jurisdictions 6 and K, will require providers in their region to adhere to new evaluation and management (E/M) services expectations for the expanded problem-focused and detailed CPT examination components. The new requirement adds specificity…
NSAIDs Increase MI Risk; Plus New Label Warnings for Canagliflozin
NSAIDs Increase Myocardial Infarction Risk According a recent meta-analysis of real-world non-steroidal anti-inflammatory drug (NSAID) use, NSAIDs may increase the risk of acute myocardial infarction (AMI). The analysis used individual patient data meta-analysis of studies from healthcare databases in Canada, Finland and the U.K. to determine the time course for risk of AMI, as well…
In-Office Pharmacist Improves Patient Care
Would your patients and practice benefit from an on-site pharmacist? Jessica Farrell, PharmD, says a pharmacist enhances patient education and frees up a rheumatologist’s time, enabling them to see more patients and provide better all-around care…
Anthem Still Weighing 2018 Obamacare Individual Participation
NEW YORK (Reuters)—Anthem Inc on Wednesday said its plans for selling 2018 Obamacare individual plans are still up in the air because of political and regulatory uncertainty, making it the latest health insurer to say questions about continued funding of government subsidies will affect consumers next year. Anthem, the biggest provider of individual health plans,…
Adding Prednisone to Methotrexate May Be Helpful in Early RA
NEW YORK (Reuters Health)—Adding prednisone to methotrexate for early rheumatoid arthritis (RA) results in a lower initiation rate of a biologic, better radiographic outcomes and no steroid-related side effects, researchers in the Netherlands say. Although biological disease-modifying anti-rheumatic drugs (bDMARDs) have led to better control of RA and improved functioning and quality of life, they…
U.K. Competition Watchdog Accuses Merck of Obstructing Biosimilars
LONDON (Reuters)—Britain’s competition watchdog has accused Merck & Co of operating an unfair discount scheme for its medicine Remicade (infliximab) that it said was designed to restrict competition from so-called biosimilar copies. The Competition and Markets Authority (CMA) says it had provisionally found the U.S. company’s European unit, Merck Sharp & Dohme (MSD), had abused…
Heart Safety Clouds Hopes for Amgen, UCB Bone Drug Approval
(Reuters)—Amgen Inc. and UCB SA no longer expect their experimental osteoporosis drug to win U.S. approval this year after a higher rate of serious heart-related side effects were observed in a late-stage clinical trial. The drug, romosozumab, which would be sold under the brand name Evenity if approved, is awaiting an approval decision by the…
- « Previous Page
- 1
- …
- 195
- 196
- 197
- 198
- 199
- …
- 310
- Next Page »